Home > HDAC & HDAC & HDAC & > M344

M344

M-344,M 344

M344是HDAC抑制剂，能在MCF-7细胞中诱导Puma和Bax基因的表达，以及凋亡形态学特征的出现。

目录号
EY1676
EY1676
EY1676
纯度
99.34%
99.34%
99.34%
规格
5 mg
10 mg
50 mg
原价
792
1245
3720
售价
792
1245
3720
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    M344 is a potent HDAC inhibitor with IC50 of 100 nM and able to induce cell differentiation.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0 - 50 μM

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Jung M, et al. J Med Chem. 1999, 42(22), 4669-4679.

    分子式
    C16H25N3O3    		 分子量
    307.39    		 CAS号
    251456-60-7     		储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    64 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    5 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01578343 Mantle Cell Lymphoma Drug: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat Samsung Medical Center|Seok Jin Kim Phase 2 2012-06-01 2016-04-13
    NCT01045538 Gastric Cancer|Histone Deacetylase Inhibitor Drug: Vorinostat, capecitabine, and cisplatin Asan Medical Center Phase 1|Phase 2 2010-02-01 2016-07-01
    NCT01500538 Follicular Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma Drug: Eltrombopag and Vorinostat Peter MacCallum Cancer Centre, Australia|GlaxoSmithKline|Merck Sharp & Dohme Corp. Phase 2 2012-10-01 2016-02-12
    NCT00918489 Soft Tissue Sarcoma Drug: Vorinostat Heidelberg University|Merck Sharp & Dohme Corp. Phase 2 2010-05-01 2014-12-03
    NCT01023737 Malignant Solid Tumour Drug: Hydroxychloroquine|Drug: Vorinostat Devalingam Mahalingam|Merck Sharp & Dohme Corp.|The University of Texas Health Science Center at San Antonio Phase 1 2009-11-01 2016-09-20
    NCT00801151 Malignant Solid Tumour Drug: Zolinza (vorinostat), vinorelbine Institut Claudius Regaud|Merck Sharp & Dohme Corp. Phase 1 2009-01-01 2010-05-19
    NCT00875745 Leukemia, Myeloid, Acute|Leukemia, Promyelocytic, Acute|Myelodysplastic Syndromes Drug: Sorafenib-Vorinostat Indiana University School of Medicine|Bayer|Indiana University Phase 1 2009-04-01 2014-09-17
    NCT00702962 Small Cell Lung Cancer Drug: Vorinostat, Carboplatin, Etoposide|Other: SAHA Milton S. Hershey Medical Center|Merck Sharp & Dohme Corp. Phase 1|Phase 2 2008-09-01 2017-01-26
    NCT01365065 HIV Positive Drug: Vorinostat Bayside Health|Merck Sharp & Dohme Corp. Phase 2 2011-05-01 2012-12-03
    NCT00838929 Brain Metastases Drug: Vorinostat|Radiation: Radiation Therapy Sidney Kimmel Cancer Center at Thomas Jefferson University|Merck Sharp & Dohme Corp.|Thomas Jefferson University Phase 1 2009-03-01 2016-10-19
    NCT03022565 Uveal Melanoma Drug: Vorinostat Nicolas Acquavella|University of Miami Sylvester Comprehensive Cancer Center|University of Miami Early Phase 1 2017-04-01 2017-02-17
    NCT01194427 Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|Invasive Breast Cancer Drug: Vorinostat and Tamoxifen Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp. Phase 2 2011-03-01 2013-05-15
    NCT02151721 Non-Small-Cell Lung Carcinoma Drug: Vorinostat, gefitinib Kanazawa University Phase 1 2014-06-01 2016-08-31
    NCT00976183 Ovarian Neoplasms Drug: Vorinostat|Drug: Vorinostat Gynecologic Oncology Associates|Merck Sharp & Dohme Corp. Phase 1|Phase 2 2009-10-01 2015-03-09
    NCT02042989 Advanced Cancers Drug: MLN9708|Drug: Vorinostat M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. Phase 1 2014-06-27 2017-03-16
    NCT02707900 HIV-1 Infection Drug: Vorinostat|Biological: AGS-004 Cynthia L Gay, MD|National Institute of Allergy and Infectious Diseases (NIAID)|University of North Carolina, Chapel Hill Phase 1 2016-03-01 2016-09-20
    NCT01266031 Malignant Glioma|Recurrent Glioblastoma Drug: vorinostat|Drug: bevacizumab National Cancer Institute (NCI)|M.D. Anderson Cancer Center|Genentech, Inc.|Merck Sharp & Dohme Corp.|Brain Tumor Trials Collaborative|Ohio State University Wexner Medical Center|Northwestern University Feinberg School of Medicine|UF Health Cancer Center at Orlando Health|Baylor Health Care System|MUSC Hollings Cancer Center|University of Utah Health System|Univeristy of Washington Medical Center|Henry Ford Health System|Columbia University|Rush University Medical Center|NorthShore University HealthSystem|The Cleveland Clinic|University of North Carolina, Chapel Hill|Washington University School of Medicine|Texas Oncology-Austin|National Institutes of Health Clinical Center (CC) Phase 1|Phase 2 2011-07-12 2017-02-21
    NCT01339871 Advanced Cancer Drug: Pazopanib|Drug: Vorinostat M.D. Anderson Cancer Center Phase 1 2011-04-01 2016-12-27
    NCT00831493 Pancreatic Cancer Radiation: Chemoradiation (Radiation Therapy)|Drug: Vorinostat M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp. Phase 1|Phase 2 2009-05-01 2012-02-27
    NCT00697476 Small Cell Lung Cancer Drug: topotecan, vorinostat Armando Santoro, MD|Istituto Clinico Humanitas Phase 1|Phase 2 2009-01-01 2013-05-27

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：